A risk oriented model to assess strategic decisions in new product development projects

F. Marmier,Didier Gourc,Frederic Laarz

DOI: https://doi.org/10.1016/j.dss.2013.05.002

IF: 6.969

2013-12-01

Decision Support Systems

Abstract:

What problem does this paper attempt to address?

Malfunction and countermeasures of Da Vinci robotic surgery system in a single-center

Zhen Wang,Weidong Gan,Gutian Zhang,Xiaogong Li,Hongqian Guo

DOI: https://doi.org/10.3877/cma.j.issn.1674-3253.2017.04.002

2017-01-01

Abstract:Objective To explore the reasons of the malfunctions of the Da Vinci robotic surgery system and propose countermeasures and preventions for the malfunctions.Methods The malfunction data occurred during 1000 cases which underwent robot-assisted urologic surgery from September 2014 to December 2016 were retrospectively analyzed.One thousand cases were divided into 5 groups on average according to the time sequence.The numbers of malfunctions for each group and days that each group underwent were counted separately.Results A total of 15 malfunction cases occurred during 1000 robot-assisted urology surgeries,with total malfunction rate of 1.5％.Recoverable malfunctions counted for 73.3％(11/15) and critical malfunctions counted for 26.7％ (4/15).Areas of malfunctions included the robotic arm system (33.3％),endoscopic instrument (20.0％),video system (20.0％),power system (13.3％),patient-side cart (6.7％) and surgeon console (6.7％).All the malfunctions were pure robot system malfunctions without instrument malfunctions.One endoscopic instrument malfunction occurred during the surgery resulted in a conversion and other three malfunctions lead to delay of surgeries.The malfunction rates of the five groups gradually rose in the early stage and decreased in the end.Conclusion The malfunction rate of Da Vinci robot surgery system was extremely low and changed under the combined influence of the two main factors,the surgeon and the Da Vinci robot.Critical malfunction is rear,which may have great impact on surgery once it occurs.
Closure to Discussion on “Virtual Damping Flux-Based LVRT Control for DFIG-Based Wind Turbine”

Rongwu Zhu,Zhe Chen

DOI: https://doi.org/10.1109/TEC.2016.2517442

IF: 4.8767

2016-01-25

IEEE Transactions on Energy Conversion

Abstract:Presents a closure to the discussion on the paper, “Virtual damping flux-based LVRT control for DFIG-based wind turbine,” (Zhu, R., et al; IEEE Trans. Energy Convers., vol. 30, pp. 714–725, Jun. 2015.
Adverse Events in Robotic Surgery: A Retrospective Study of 14 Years of FDA Data

Homa Alemzadeh,Jaishankar Raman,Nancy Leveson,Zbigniew Kalbarczyk,Ravishankar K. Iyer

DOI: https://doi.org/10.1371/journal.pone.0151470

IF: 3.7

2016-04-20

PLoS ONE

Abstract:BACKGROUND: Use of robotic systems for minimally invasive surgery has rapidly increased during the last decade. Understanding the causes of adverse events and their impact on patients in robot-assisted surgery will help improve systems and operational practices to avoid incidents in the future.METHODS: By developing an automated natural language processing tool, we performed a comprehensive analysis of the adverse events reported to the publicly available MAUDE database (maintained by the U.S. Food and Drug Administration) from 2000 to 2013. We determined the number of events reported per procedure and per surgical specialty, the most common types of device malfunctions and their impact on patients, and the potential causes for catastrophic events such as patient injuries and deaths.RESULTS: During the study period, 144 deaths (1.4% of the 10,624 reports), 1,391 patient injuries (13.1%), and 8,061 device malfunctions (75.9%) were reported. The numbers of injury and death events per procedure have stayed relatively constant (mean = 83.4, 95% confidence interval (CI), 74.2-92.7 per 100,000 procedures) over the years. Surgical specialties for which robots are extensively used, such as gynecology and urology, had lower numbers of injuries, deaths, and conversions per procedure than more complex surgeries, such as cardiothoracic and head and neck (106.3 vs. 232.9 per 100,000 procedures, Risk Ratio = 2.2, 95% CI, 1.9-2.6). Device and instrument malfunctions, such as falling of burnt/broken pieces of instruments into the patient (14.7%), electrical arcing of instruments (10.5%), unintended operation of instruments (8.6%), system errors (5%), and video/imaging problems (2.6%), constituted a major part of the reports. Device malfunctions impacted patients in terms of injuries or procedure interruptions. In 1,104 (10.4%) of all the events, the procedure was interrupted to restart the system (3.1%), to convert the procedure to non-robotic techniques (7.3%), or to reschedule it (2.5%).CONCLUSIONS: Despite widespread adoption of robotic systems for minimally invasive surgery in the U.S., a non-negligible number of technical difficulties and complications are still being experienced during procedures. Adoption of advanced techniques in design and operation of robotic surgical systems and enhanced mechanisms for adverse event reporting may reduce these preventable incidents in the future.

multidisciplinary sciences
The COMPARE Study: Comparing Perioperative Outcomes of Oncologic Minimally Invasive Laparoscopic, Da Vinci Robotic, and Open Procedures: A Systematic Review and meta-analysis of The Evidence

Rocco Ricciardi,Usha Seshadri-Kreaden,Ana Yankovsky,Douglas Dahl,Hugh Auchincloss,Neera M Patel,April E Hebert,Valena Wright

DOI: https://doi.org/10.1097/SLA.0000000000006572

2024-10-22

Abstract:Objective: To assess 30-day outcomes of da Vinci robotic-assisted (dV-RAS) versus laparoscopic/thoracoscopic (lap/VATS) or open oncologic surgery. Summary background data: Complex procedures in deep/narrow spaces especially benefit from dV-RAS. Prior procedure-specific comparisons are not generalizable. Methods: PubMed, Scopus and EMBASE were systematically searched (latest: 11/17/2023) following PRISMA and PROSPERO (Reg#CRD42023466759). Randomized, prospective, and database studies were pooled as odds ratios (OR) or mean differences (MD) in R using fixed-effect or random-effects (heterogeneity significant). ROBINS-I/RoB 2 were used to assess bias. Results: Of 56,314 unique references over 12 years from 22 countries, 230 studies (34 randomized, 74 prospective, 122 database) comparing dV-RAS to lap/VATS or open surgery across 7 procedures, 4 specialties, representing 1,194,559 dV-RAS; 1,095,936 lap/VATS and 1,625,320 open cases were included. Operative time for dV-RAS was longer than lap/VATS (MD:17.73min [9.80,25.67], P <0.01) and open surgery (MD:40.92min [28.83,53.00], P <0.01), whereas hospital stay was shorter (lap/VATS MD:-0.51d [-0.64,-0.38], P <0.01; open MD:-1.85d [-2.09,-1.62], P <0.01) and blood loss was less versus open (MD:-293.44ml [-359.53,-227.35]). There were fewer dV-RAS conversions (OR:0.44 [0.40,0.49], P <0.01), transfusions (OR:0.79 [0.72,0.88], P <0.01), postoperative complications (OR:0.90 [0.84,0.96], P <0.01), readmissions (OR:0.91 [0.83,0.99], P =0.04), and deaths (OR:0.86 [0.81,0.92], P <0.01) versus lap/VATS, and fewer transfusions (OR:0.25 [0.21,0.30], P <0.01), postoperative complications (OR:0.56 [0.52,0.61], P <0.01), readmissions (OR:0.71 [0.63,0.81], P <0.01), reoperations (OR:0.89 [0.81,0.97], P <0.01), and deaths (OR:0.54 [0.47,0.63], P <0.01) versus open surgery. Blood loss (MD:-12.26mL [-29.44,4.91], P =0.16) and reoperations (OR:1.03 [0.95,1.11], P =0.48) were similar for dV-RAS and lap/VATS. There was significant heterogeneity. Conclusions: Da Vinci -RAS confers benefits across oncological procedures and study designs. These results provide clinical evidence to multi-specialty-care decision-makers considering dV-RAS.
[Cloning of group A streptococcal pyrogenic exotoxin-B gene and its recombinant protein expression in culture supernatant].

Y. Watanabe

DOI: https://doi.org/10.1272/JNMS.68.222

2001-06-01

Abstract:Streptococcal pyrogenic exotoxin B, a conserved cysteine protease (SPE B/SCP) released by group A Streptococcus (GAS) strains, is considered to be an important virulence factor of this bacterium. This paper reports the cloning of gene encoding SPE B/SCP. For production of recombinant SPE B/SCP (rSPE B/SCP), the primers specific for the SPE B/SCP gene (spe b) were designed based on its nucleotide sequence. Polymerase chain reaction (PCR) was performed with the genomic DNA of GAS strain NZ131 as a template. The amplified PCR products were purified and cloned into the pBluescript II SK(+) plasmid vector. The vector was transformed into Escherichia coli (E. coli) JM109. The rSPE B/SCP and its recombinant proenzyme (rzym) were secreted in the culture supernate of the transformant. The rSPE B/SCP was purified from the supernatant by sequential chromatography on DEAE-Sepharose, matrix gel Red A and Sephadex G-50 columns. The purified rzym and rSPE B/SCP, respectively, gave a single band with a molecular weight approximately 40 kDa and 27 kDa on SDS-polyacrylamide gel electrophoresis, and reacted with anti-SPE B/SCP antibodies in Western Blot analysis. This is the first report in which rSPE B/SCP was obtained from the culture supernate of the transformant.
Learning Curve for Single-port Robot-assisted Urological Surgery: Single-center Experience and Implications for Adoption

Antony A Pellegrino,Francesco Pellegrino,Donato Cannoletta,Ruben Sauer Calvo,Juan Torres Anguiano,Luca Morgantini,Alberto Briganti,Francesco Montorsi,Simone Crivellaro

DOI: https://doi.org/10.1016/j.euf.2024.09.005

2024-09-19

Abstract:Background and objective: Understanding the learning curve for the da Vinci single-port (SP) surgical robot is crucial for adoption, training, and enhancement of surgical safety and efficiency. Our aim was to assess the impact of both overall experience (O-EXP) and procedure-specific experience (PS-EXP) on perioperative outcomes across various SP surgeries. Methods: We analyzed data for 387 consecutive SP surgeries conducted by a high-volume surgeon from December 2018 to July 2023. These included SP robot-assisted radical prostatectomy (SP-RARP), robot-assisted simple prostatectomy (SP-RASP), and robot-assisted nephrectomy (SP-RANP). We used multivariable logistic regression to evaluate the relationship between surgeon experience and outcomes, and locally weighted scatterplot smoothing analysis to graphically explore the risk of postoperative complications according to O-EXP. Key findings and limitations: The 387 SP procedures assessed included 172 (44%) SP-RARP, 53 (14%) SP-RASP, and 162 (42%) SP-RANP cases. Overall, 17% of patients had a complication of any grade, 6% experienced severe complications (Clavien-Dindo grade ≥3), and 8% required readmission. Both O-EXP and PS-EXP were associated with a lower risk of complications. The odds ratios for the incidence of complications per increment of 10 procedures were 0.83 (95% confidence interval [CI] 0.76-0.89) for PS-EXP and 0.93 (95% CI 0.90-0.96) for O-EXP. PS-EXP was also associated with a shorter operative time (β = -3.9, 95% CI -4.9 to -2.9). The risk of complications reached a minimum at 30 SP-RASP, 70 SP-RANP, and 150 SP-RARP cases. Our study is limited by its retrospective design, single-surgeon experience, and lack of functional outcome assessment. Conclusions and clinical implications: Robot-assisted surgery with the da Vinci SP robot has a distinctive learning curve that is influenced by the platform and procedure-specific characteristics. For surgeons new to SP surgery, RASP and renal procedures had the earliest learning curve success and should be approached first, with RARP attempted only when the surgeon has become accustomed to the SP platform. Patient summary: We investigated the learning curve for a surgical robot that uses just one keyhole incision. We found that the time to reach proficiency for urological surgeries with this specific robot, measured as the rate of complications, is faster for some procedures than for more complex operations. This information can help in improving surgeon training and patient safety.
Cost analysis of new robotic competitors: a comparison of direct costs for initial hospital stay between Da Vinci and Hugo RAS for radical prostatectomy

Maria Chiara Sighinolfi,Luigi Amerigo Messina,Matteo Stocco,Marcio Covas Moscovas,Paolo Pelliccia,Alessia Palma,Marta Rossini,Angela Gallo,Augusto Ramondo,Efrem Pozzi,Simone Assumma,Stefano Terzoni,Marco Sandri,Vipul Patel,Bernardo Rocco

DOI: https://doi.org/10.1007/s11701-024-01930-w

2024-06-13

Abstract:Robotic surgery with Da Vinci has revolutionized the treatment of several diseases, including prostate cancer; nevertheless, costs remain the major drawback. Recently, new robotic platforms entered the market aiming to reduce costs and improve the access to robotic surgery. The aim of the study is to compare direct cost for initial hospital stay of radical prostatectomy performed with two different robotic systems, the Da Vinci and the new Hugo RAS system. This is a projection study that applies cost of robotic surgery, derived from a local tender, to the clinical course of robotic radical prostatectomy (RALP) performed with Da Vinci and Hugo RAS. The study was performed in a public referral center for robotic surgery equipped with both systems. The cost of robotic surgery from a local tender were considered and included rent, annual maintenance, and a per-procedure fee covering the setup of four robotic instruments. Those costs were applied to patients who underwent RALP with both systems since November 2022. The primary endpoint is to evaluate direct costs of initial hospital stay for Da Vinci and Hugo RAS, by considering equipment costs (as derived from the tender), and costs of theater and of hospitalization. The direct per-procedure cost is €2,246.31 for a Da Vinci procedure and €1995 for a Hugo RALP. In the local setting, Hugo RAS provides 11% of cost saving for RALP. By applying this per-procedure cost to our clinical data, the expenditure for the entire index hospitalization is € 6.7755,1 for Da Vinci and € 6.637,15 for Hugo RALP. The new Hugo RAS system is willing to reduce direct expenditures of robotic surgery for RALP; furthermore, it provides similar peri-operative outcomes compared to the Da Vinci. However, other drivers of costs should be taken into account, such as the duration of OR use-that is more than just console time and may depend on the facility's background and organization. Further variations in direct costs of robotic systems are related to caseload, local agreements and negotiations. Thus, cost comparison of new robotic platform still remains an ongoing issue.
A prospective comparison of robotic and laparoscopic pyeloplasty

Richard E Link,Sam B Bhayani,Louis R Kavoussi

DOI: https://doi.org/10.1097/01.sla.0000205626.71982.32

Abstract:Objective: To determine whether robotic-assisted pyeloplasty (RLP) has any significant clinical or cost advantages over laparoscopic pyeloplasty (LP) for surgeons already facile with intracorporeal suturing. Summary background data: LP has become an established management approach for primary ureteropelvic junction obstruction. More recently, the da Vinci robot has been applied to this procedure (RLP) in an attempt to shorten the learning curve. Whether RLP provides any significant advantage over LP for the experienced laparoscopist remains unclear. Methods: Ten consecutive cases each of transperitoneal RLP and LP performed by a single surgeon were compared prospectively with respect to surgical times and perioperative outcomes. Cost assessment was performed by sensitivity analysis using a mathematical cost model incorporating operative time, anesthesia fees, consumables, and capital equipment depreciation. Results: The RLP and LP groups had statistically indistinguishable demographics, pathology, and similar perioperative outcomes. Mean operative and total room time for RLP was significantly longer than LP by 19.5 and 39.0 minutes, respectively. RLP was much more costly than LP (2.7 times), due to longer operative time, increased consumables costs, and depreciation of the costly da Vinci system. However, even if depreciation was eliminated, RLP was still 1.7 times as costly as LP. One-way sensitivity analysis showed that LP operative time must increase to almost 6.5 hours for it to become cost equivalent to RLP. Conclusions: For the experienced laparoscopist, application of the da Vinci robot resulted in no significant clinical advantage and added substantial cost to transperitoneal laparoscopic dismembered pyeloplasty.
1542 Robotic Single Port Laparoscopy Using the Da Vinci Sp® Surgical System For Benign Gynecologic Disease; Preliminary Report

HJ Shin,H Yoo,JH Lee,Lee,K Jeong,HS Moon,SR Lee

DOI: https://doi.org/10.1016/j.jmig.2019.09.466

IF: 4.314

2019-11-01

Journal of Minimally Invasive Gynecology

Abstract:Study ObjectiveTo report our initial experience of robotic single port laparoscopy using the da Vinci SP® surgical system for benign gynecologic diseases.DesignRetrospective cohort study.SettingAcademic tertiary care hospital.Patients or Participants31 women with benign gynecologic diseases.InterventionsRobotic single port laparoscopy.Measurements and Main ResultsFrom December to January 2019, hysterectomy, myomectomy, adnexectomy, and sacrocolpopexy were performed in 7, 12, 5, and 7 women, respectively. The mean age and body mass index of patients were 47.7±12.8 years and 22.7±3.1 kg/m2. In terms of operative outcomes, the mean docking time, operating time, estimated blood loss, and hospitalization were 2.2±2.1 minutes, 126.3±61.6 minutes, 93.9±76.9 mL, and 4.6±0.7 days. There was no laparoconversion or major complication.ConclusionRobotic single port laparoscopy using the da Vinci SP surgical system might be an alternative surgical technique for various benign gynecologic diseases However, further studies are required to clarify the feasibility and safety of the new robot surgical system.

obstetrics & gynecology
Economic evaluation of da Vinci-assisted robotic surgery: a systematic review

Giuseppe Turchetti,Ilaria Palla,Francesca Pierotti,Alfred Cuschieri

DOI: https://doi.org/10.1007/s00464-011-1936-2

2011-10-13

Surgical Endoscopy

Abstract:BackgroundHealth technology assessment (HTA) is frequently used when a new and expensive technology is being introduced into clinical practice. This certainly is the case with the da Vinci surgical robot, with costs ranging from $1 to $2.5 million for each unit. This systematic review documents major variability in the reported cost evaluation studies of da Vinci robot-assisted operations compared with those performed by the direct manual laparoscopic approach.MethodsPublished studies in the English language related to the period 2000–2010 were searched using economic and clinical electronic databases.ResultsAll 11 reports included some form of cost analysis, which made it possible for the authors to extract information on certain specific economic outcomes: operating room time, hospital stay, and total costs. With the exception of two studies, the reported operating room time was higher with the robotic approach than with manual laparoscopic surgery, and the hospital stay was the same for the two techniques. Robotic surgery is significantly more expensive if the purchase and maintenance costs of the robot system are included in the total costs. Only 3 of the 11 publications included these costs.ConclusionsThe disadvantage of robotic surgery is its higher costs related to purchase and maintenance of technology and its longer operating room time. However, emerging evidence shows that operating room time decreases with experience using the robot. From the HTA viewpoint, the result of this review is that the jury still is out on the HTA of da Vinci-assisted robotic surgery.
Surgical techniques of Da Vinci robot-assisted laparoscopic radical prostatectomy

Z. Shan

Abstract:The wide application and development of Da Vinci surgical system in the urology is a milestone in the development of clinical medicine.Da Vinci robot-assisted laparoscopic radical prostatectomy(RLRP)has the most obvious advantages of minimally invasive surgery among all robotic surgeries in urology compared to the laparoscopic surgeries.In the developed regions with high incidence of prostate cancer,RLRP has almost become the gold standard for the treatment of localized prostate cancer.Rapid development of RLRP has also been achieved in China.This review gives a brief account of the current situation and development trend of robotic surgical system and summarizes the main aspects of RLRP including the indications and contraindications,surgical procedures and techniques,advantages and disadvantages and so on.

Medicine,Engineering
Implementing a robotic liver resection program does not always require prior laparoscopic experience

Emanuele Balzano,Lorenzo Bernardi,Giovanni Tincani,Davide Ghinolfi,Fabio Melandro,Jessica Bronzoni,Sonia Meli,Giuseppe Arenga,Giandomenico Biancofiore,Laura Crocetti,Paolo De Simone

DOI: https://doi.org/10.1007/s00464-021-08645-1

2021-10-04

Surgical Endoscopy

Abstract:Abstract Background Preliminary experience in laparoscopic liver surgery is usually suggested prior to implementation of a robotic liver resection program. Methods This was a retrospective cohort analysis of patients undergoing robotic (RLR) versus laparoscopic liver resection (LLR) for hepatocellular carcinoma at a center with concomitant initiation of robotic and laparoscopic programs Results A total of 92 consecutive patients operated on between May 2014 and February 2019 were included: 40 RLR versus 52 LLR. Median age (69 vs. 67; p = 0.74), male sex (62.5% vs. 59.6%; p = 0.96), incidence of chronic liver disease (97.5% vs.98.1%; p = 0.85), median model for end-stage liver disease (MELD) score (8 vs. 9; p = 0.92), and median largest nodule size (22 vs. 24 mm) were similar between RLR and LLR. In the LLR group, there was a numerically higher incidence of nodules located in segment 4 (20.0% vs. 16.6%; p = 0.79); a numerically higher use of Pringle’s maneuver (32.7% vs. 20%; p = 0.23), and a shorter duration of surgery (median of 165.5 vs. 217.5 min; p = 0.04). Incidence of complications (25% vs.32.7%; p = 0.49), blood transfusions (2.5% vs.9.6%; p = 0.21), and median length of stay (6 vs. 5; p = 0.54) were similar between RLR and LLR. The overall (OS) and recurrence-free (RFS) survival rates at 1 and 5 years were 100 and 79 and 95 and 26% for RLR versus 96.2 and 76.9 and 84.6 and 26.9% for LLR (log-rank p = 0.65 for OS and 0.72 for RFS). Conclusions Based on our results, concurrent implementation of a robotic and laparoscopic liver resection program appears feasible and safe, and is associated with similar oncologic long-term outcomes.
Rate of occult specimen provenance complications in routine clinical practice.

J. Pfeifer,Jingxia Liu

DOI: https://doi.org/10.1309/AJCP50WEZHWIFCIV

American Journal of Clinical Pathology

Abstract:Occult specimen provenance complications (SPCs), which occur when there is an absence of any direct or indirect indication that a specimen switch or contamination may have occurred, constitute a significant patient safety and medical-legal problem because they can lead to misdiagnosis. However, the rate at which occult SPCs occur is unknown because, by definition, this category of errors is not identified by standard laboratory practices. In this study, we evaluated a data set comprising almost 13,000 prostate biopsies that were prospectively tested for specimen provenance errors as part of routine clinical practice. The frequency of occult type 1 errors (a complete transposition between patients) and type 2 errors (contamination of the patient's tissue with 1 or more unrelated patients) was 0.26% and 0.67%, respectively; every urology practice setting and surgical pathology laboratory type with a representative sample size experienced at least 1 type 1 and 1 type 2 error during the study period. Overall, the mean frequency of SPCs across practice settings was 0.22% for type 1 errors and 1.69% for type 2 errors. The type 1 rate showed no correlation with a surgical pathology laboratory setting or urologic practice group setting; the type 2 rate correlated solely with a surgical pathology laboratory setting. The occult SPC rate in this limited data set provides an estimate of the scope of the problem of potential misdiagnosis as a result of occult specimen provenance errors in routine clinical practice.
Suitability of the MP1000 Platform for Robot-assisted Prostatectomy: A Prospective Randomised Controlled Trial

Shaoxi Niu,Liyan Ao,Yu Gao,Fangjian Zhou,Wang He,Jin Tao,Shengjie Guo,Baojun Wang,Xing Ai,Hongzhao Li,Xin Ma,Xuepei Zhang,Jian Huang,Xu Zhang

DOI: https://doi.org/10.1016/j.euros.2024.02.017

IF: 3

2024-04-26

European Urology Open Science

Abstract:Background and objective Robot-assisted radical prostatectomy (RARP) is widely used because of the many advantages of a robotic approach. The da Vinci Si robot is one of the most commonly used surgical robot systems, but it may be associated with higher costs owing to the use of consumable surgical supplies. Our aim was to conduct a preliminary investigation of the capability of the MP1000 system for RARP. Methods In this prospective, multicentre, single-blinded study, we randomly assigned 42 patients scheduled to undergo RARP between April and September 2021 to a da Vinci Si group (control) or an MP1000 group (intervention). Patients underwent RARP performed using the assigned robotic system and were followed up at 3-mo intervals. The primary outcome was the rate of conversion to open/laparoscopic surgery. Secondary outcomes were installation and operation times, intraoperative blood loss, postoperative surgical margin status, hospital stay, incontinence, complications, safety indicators, and surgeon ergonomics. Key findings and limitations All procedures were successfully completed without conversion to open/laparascopic surgery or major complications. Secondary outcomes, including oncological and ergonomic indicators, did not differ significantly between the groups over the study period. One patient in the control group experienced dysuria (Clavien-Dindo grade 3). No patients had incontinence at 3 mo. A limitation of the study is the small sample size. Conclusions and clinical implications RARP with the MP1000 system is feasible, safe, and effective in the management of localised prostate cancer. Patient summary We assessed the effectiveness and safety of the new MP1000 robot system for robot-assisted removal of the prostate in comparison to the da Vinci Si robot. We found no difference in effectiveness or safety among 42 patients with prostate cancer who were assigned randomly to one of the two systems. We conclude that the MP1000 is a suitable robot for this surgery.

urology & nephrology
Robot-assisted laparoscopic radical prostatectomy of 130 cases

LIU Yu-jun,GUO Jian-ming,WU Rui-yi,XU Ming,RONG Rui-ming,ZHU Yan-jun,CHEN Wei,ZHANG Jian-ping,JIANG Shuai,XU Lei,YANG Yuan-feng,WANG Hang,ZHU Tong-yu

2013-01-01

Abstract:Objective To assess the efficiency and safety of robot-assisted laparoscopic radical prostectomy(RARP). Methods A retrospective chart review was perfomed, 130 patients radical prostatectomy(RARP) with da Vinci S surgical system(da Vinci Intuitive Surgical Inc.,Sunnyvale,CA, USA)from July 2009 to September 2013 localized prostate cancer underwent robot-assisted. The clinical data of patients underwent RARP were analyzed. The age range was 48 ~ 76years,mean(67 ± 6)years. The PSA level range was 2.16 ~ 78.20ng/mL,mean(26.05 ± 8.41)ng/mL. Gleason score was 6 ~ 10. Tumor clinical stage of all patients are localized prostate cancer. Results All 130 patients received successful robot-assisted operation and encountered no technique events. A five or six ports transperitonealapproach using a 3 or 4-arm da Vinci S surgical system was used to perform RARP. The preoperative set- up time of the da Vinci S surgical system was 20 ~ 90min,mean(48.5 ± 15.4)min. The operating time range was 90 ~ 300min,mean(143.6 ± 22.9)min. The estimated blood loss was 50-600ml,mean( 158.2 ± 59.6)ml,and 2(1.5%)patients need transfusion. The patients were ambulant between 2nd and 3rd postoperative day,mean(2.2 ± 0.6)d and discharged on postoperative day 5 to 21,mean(6.6 ± 1.9)d. Foley catheter was removed on postoperative day 4 to 21,mean(6.1 ± 2.0)d. The main postoperative complications including:the urinary leak in six patients(4.6%),prolonged lymphorrhea in eight patients(6.2%),but not presented any form of lymphocele. Deep vein thrombosis,pulmonary embolism and epididymitis presented in one patient respectively. Histopathology confirmed in positive surgical margin 12(9.2%)cases,seminal vesicle invasion in 10(7.7%)cases and lymph node invasion in 4(3.1%)cases. The PSA was less than 0.2 ng/ml during follow-up of one to twelve months postoperatively. The pad-free continence rate was 86% and 95% in postoperative month 6 and one year respectively. Conclusions Robot-assisted laparoscopic radical prostatectomy has the advantage of mini-invasiveness,less blood loss, rapid postoperative recovery. It is safe,reliable and feasible. RARP should be taken as the first choice for radical prostatectomy.
Robot-Assisted Radical Prostatectomy by the Hugo Robotic-Assisted Surgery (RAS) System and the da Vinci System: A Comparison between the Two Platforms

Hsien-Che Ou,Lucian Marian,Ching-Chia Li,Yung-Shun Juan,Min-Che Tung,Hung-Jen Shih,Chin-Po Chang,Jian-Ting Chen,Che-Hsueh Yang,Yen-Chuan Ou

DOI: https://doi.org/10.3390/cancers16061207

2024-03-20

Cancers

Abstract:Objective: In a previous study, we proved that an experienced urologist is more likely to adapt to the Hugo RAS system. Based on this, we further examine various parameters in this study. Parameters included in this study consisted of console time, functional outcomes, and oncological outcomes. Materials and Methods: A total of 60 patients who underwent robot-assisted radical prostatectomy (RARP) performed by a single surgeon using the da Vinci (DV) system (n = 30) or the Hugo RAS system (n = 30) between March 2023 and August 2023 were included in the analysis. The intraoperative operative time was categorized into vesicourethral anastomosis time and overall console time. Functional and oncological outcomes were documented at the 1st and 3rd postoperative months. Parametric and non-parametric methods were adopted after checking skewness and kurtosis, and an α value of 5% was used to determine the significance. Results: The vesicourethral anastomosis time was significantly lengthened (Hedge's g: 0.87; 95% confidence interval (CI): 0.34–1.39; J factor = 0.987). However, the overall console time was not affected. The functional (postoperative 3rd month: p = 0.130) and oncological outcomes (postoperative 3rd month: p = 0.103) were not significantly different. We also found that the adverse effect on surgical specimens and positive surgical margins was not affected (p = 0.552). Conclusion: During the process of adaptation, although intricate motions (such as the vesicourethral anastomosis time) would be lengthened, the overall console time would not change remarkably. In this process, the functional and oncological outcomes would not be compromised. This encourages urologists to adopt the Hugo RAS system in RARP if they have previous experiences of using the DV system, since their trifecta advantage would not be compromised.

oncology
Robotic vs. laparoscopic liver surgery: a single-center analysis of 600 consecutive patients in 6 years

Moritz Schmelzle,Linda Feldbrügge,Santiago Andres Ortiz Galindo,Simon Moosburner,Anika Kästner,Felix Krenzien,Christian Benzing,Matthias Biebl,Robert Öllinger,Thomas Malinka,Wenzel Schöning,Johann Pratschke

DOI: https://doi.org/10.1007/s00464-021-08770-x

2022-05-31

Surgical Endoscopy

Abstract:Abstract Background While laparoscopic liver surgery has become a standard procedure, experience with robotic liver surgery is still limited. The aim of this prospective study was to evaluate safety and feasibility of robotic liver surgery and compare outcomes with conventional laparoscopy. Methods We here report the results of a single-center, prospective, post-marketing observational study (DRKS00017229) investigating the safety and feasibility of robotic liver surgery. Baseline characteristics, surgical complexity (using the IWATE score), and postoperative outcomes were then compared to laparoscopic liver resections performed at our center between January 2015 and December 2020. A propensity score-based matching (PSM) was applied to control for selection bias. Results One hundred twenty nine robotic liver resections were performed using the da Vinci Xi surgical system (Intuitive) in this prospective study and were compared to 471 consecutive laparoscopic liver resections. After PSM, both groups comprised 129 cases with similar baseline characteristics and surgical complexity. There were no significant differences in intraoperative variables, such as need for red blood cell transfusion, duration of surgery, or conversion to open surgery. Postoperative complications were comparable after robotic and laparoscopic surgery (Clavien–Dindo ≥ 3a: 23% vs. 19%, p = 0.625); however, there were more bile leakages grade B–C in the robotic group (17% vs. 7%, p = 0.006). Length of stay and oncological short-term outcomes were comparable. Conclusions We propose robotic liver resection as a safe and feasible alternative to established laparoscopic techniques. The object of future studies must be to define interventions where robotic techniques are superior to conventional laparoscopy.

surgery
Use of the SNOT-22 and UPSIT to appropriately select pediatric patients with cystic fibrosis who should be referred to an otolaryngologist: cross-sectional study.

A. Thamboo,R. D. Santos,L. Naidoo,R. Rahmanian,M. Chilvers,N. Chadha

DOI: https://doi.org/10.1001/jamaoto.2014.1650

2014-10-01

JAMA Otolaryngology - Head and Neck Surgery

Abstract:IMPORTANCE Sinonasal disease and, specifically, nasal polyps, occur frequently in children with cystic fibrosis (CF). As survival rates have improved, it has become imperative that otolaryngologists become involved in the care of patients with CF to provide appropriate medical and surgical interventions for sinonasal disease. Despite significant variability in the subjective reporting of clinical symptoms, previous work has suggested there may be a relationship between clinical indicators and sinonasal disease in this population. OBJECTIVE To determine whether the 22-item Sino-Nasal Outcome Test (SNOT-22), the University of Pennsylvania Smell Identification Test (UPSIT), and other measures of sinonasal disease could be used to predict the presence of subclinical nasal polyps in children with CF. DESIGN, SETTING, AND PARTICIPANTS This was a cross-sectional study performed from May 2012 through April 2013 at a cystic fibrosis clinic at BC Children's Hospital in Vancouver, British Columbia, Canada. There were 72 eligible children with CF for this study (with a confirmed diagnosis of CF based on genetic testing; their ages ranged from 6 to 18 years, and they were not actively being treated by an otolaryngologist). Thirty-seven of these patients (23 males, 14 females) consented to participate in this study. Twenty-three declined participation, and 12 could not be contacted. MAIN OUTCOMES AND MEASURES Potential clinical predictors for the presence of subclinical nasal polyps were determined a priori. All 37 recruited participants completed a full study assessment. Nasal endoscopy (the gold standard) was performed to determine the presence of nasal polyps. Potential predictors that were assessed included age, sex, genotype, pancreatic function, SNOT-22 and UPSIT scores, oral culture swab result, and severity of forced expiratory volume in 1 second (FEV(1)). RESULTS A SNOT-22 score of greater than 11 was the only statistically significant predictor of nasal polyps (P = .04). The positive predictive value was 68.1%, the negative predictive value was 66.7%, and the positive likelihood ratio was 1.82. CONCLUSIONS AND RELEVANCE Given that the SNOT-22 is easy to administer and inexpensive, this sinus disease-specific questionnaire seems to be an appropriate tool for routine use by respirologists when assessing patients with CF to help predict subclinical nasal polyps.
Surgical outcomes of robot-assisted rectal cancer surgery using the da Vinci Surgical System: a multi-center pilot Phase II study

Shunsuke Tsukamoto,Yuji Nishizawa,Hiroki Ochiai,Yuichiro Tsukada,Takeshi Sasaki,Dai Shida,Masaaki Ito,Yukihide Kanemitsu

DOI: https://doi.org/10.1093/jjco/hyx141

IF: 2.925

2017-09-21

Japanese Journal of Clinical Oncology

Abstract:INTRODUCTION: We conducted a multi-center pilot Phase II study to examine the safety of robotic rectal cancer surgery performed using the da Vinci Surgical System during the introduction period of robotic rectal surgery at two institutes based on surgical outcomes.METHODS: This study was conducted with a prospective, multi-center, single-arm, open-label design to assess the safety and feasibility of robotic surgery for rectal cancer (da Vinci Surgical System). The primary endpoint was the rate of adverse events during and after robotic surgery. The secondary endpoint was the completion rate of robotic surgery.RESULTS: Between April 2014 and July 2016, 50 patients were enrolled in this study. Of these, 10 (20%) had rectosigmoid cancer, 17 (34%) had upper rectal cancer, and 23 (46%) had lower rectal cancer; six underwent high anterior resection, 32 underwent low anterior resection, 11 underwent intersphincteric resection, and one underwent abdominoperineal resection. Pathological stages were Stage 0 in 1 patient, Stage I in 28 patients, Stage II in 7 patients and Stage III in 14 patients. Pathologically complete resection was achieved in all patients. There was no intraoperative organ damage or postoperative mortality. Eight (16%) patients developed complications of all grades, of which 2 (4%) were Grade 3 or higher, including anastomotic leakage (2%) and conversion to open surgery (2%).CONCLUSION: The present study demonstrates the feasibility and safety of robotic rectal cancer surgery, as reflected by low morbidity and low conversion rates, during the introduction period.

oncology
Initial experience of treating prostate cancer patients with coronary artery disease through robot-assisted radical Prostatectomy

Shuai JIANG,Jianming GUO,Li'an SUN,Ruiyi WU,Jianping ZHANG,Li LIU,Hang WANG,Yanjun ZHU,Zhibing XU

DOI: https://doi.org/10.13201/j.issn.1001-1420.2017.08.006

2017-01-01

Journal of Clinical Urology

Abstract:Objective:To explore the safety and efficiency of Da Vinci robot treating prostate cancer patients with coronary artery disease.Method:We retrospectively analyzed the perioperative data of prostate cancer patients with coronary artery disease from Jul.2012 to Feb.2017 in our department.Result:Thirty-one patients with prostate cancer and coronary artery disease were included in the study.Their average age was 68 (range,58-78) years old.Total PSA before surgery was 17.0 (range,1.81-66.0) ng/ml.All of the surgeries were successful.The withdrawal period of anticoagulant drug before surgery was 8.8 (range,6 21) days.The set up time of Da Vinci robot system was 21 (range,13-40) min.The average operation time was 139 (range,90-230) min.The amount of blood loss during surgery was 161 (range,20-450) ml.No surgery converted to open.No postoperative complication was observed.The mean hospital stay was 12 (range,7-25) days.The mean catheter retention duration was 15 (range.7-23) days.The mean PSA level six weeks after surgery was 0.07 (range,0-0.5) ng/ml.Conclusion:The Da Vinci robot system is effect and safe in the patients with prostate cancer and coronary artery disease.

A risk oriented model to assess strategic decisions in new product development projects

Malfunction and countermeasures of Da Vinci robotic surgery system in a single-center

Closure to Discussion on “Virtual Damping Flux-Based LVRT Control for DFIG-Based Wind Turbine”

Adverse Events in Robotic Surgery: A Retrospective Study of 14 Years of FDA Data

The COMPARE Study: Comparing Perioperative Outcomes of Oncologic Minimally Invasive Laparoscopic, Da Vinci Robotic, and Open Procedures: A Systematic Review and meta-analysis of The Evidence

[Cloning of group A streptococcal pyrogenic exotoxin-B gene and its recombinant protein expression in culture supernatant].

Learning Curve for Single-port Robot-assisted Urological Surgery: Single-center Experience and Implications for Adoption

Cost analysis of new robotic competitors: a comparison of direct costs for initial hospital stay between Da Vinci and Hugo RAS for radical prostatectomy

A prospective comparison of robotic and laparoscopic pyeloplasty

1542 Robotic Single Port Laparoscopy Using the Da Vinci Sp® Surgical System For Benign Gynecologic Disease; Preliminary Report

Economic evaluation of da Vinci-assisted robotic surgery: a systematic review

Surgical techniques of Da Vinci robot-assisted laparoscopic radical prostatectomy

Implementing a robotic liver resection program does not always require prior laparoscopic experience

Rate of occult specimen provenance complications in routine clinical practice.

Suitability of the MP1000 Platform for Robot-assisted Prostatectomy: A Prospective Randomised Controlled Trial

Robot-assisted laparoscopic radical prostatectomy of 130 cases

Robot-Assisted Radical Prostatectomy by the Hugo Robotic-Assisted Surgery (RAS) System and the da Vinci System: A Comparison between the Two Platforms

Robotic vs. laparoscopic liver surgery: a single-center analysis of 600 consecutive patients in 6 years

Use of the SNOT-22 and UPSIT to appropriately select pediatric patients with cystic fibrosis who should be referred to an otolaryngologist: cross-sectional study.

Surgical outcomes of robot-assisted rectal cancer surgery using the da Vinci Surgical System: a multi-center pilot Phase II study

Initial experience of treating prostate cancer patients with coronary artery disease through robot-assisted radical Prostatectomy